Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-09 | Brian L. Kotzin, M.D., age 70, joined us as a director in August 2017. ... The following three directors are the current members of the Audit Committee: Mr. Goodwin, Mr. Katkin and Mr. Lapointe. ... The following three directors are the members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Mr. Lapointe, Dr. Ringrose, and Dr. Kotzin. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2018: Brian L. Kotzin 62,500 fees earned in cash, 103,664 option awards, total 166,164. |
| 2020-04-01 | Brian L. Kotzin, M.D., age 71, joined us as a director in August 2017. ... The following three directors are the members of the Scientific and Clinical Trial Advisory Committee: Dr. Moos, Dr. Kotzin and Ms. Wasman, who replaced Dr. Ringrose upon his retirement in May of 2019. Dr. Kotzin serves as Chair. ... For services provided in 2019, each non-employee director received, paid on a quarterly basis for quarters served, a yearly retainer of $50,000. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2019: Brian L. Kotzin, M.D. Fees Earned or Paid in Cash $88,750, Option Awards $22,917, Total $111,667. |
| 2022-04-05 | Brian L. Kotzin, M.D., age 73, joined us as a director in August 2017. A board-certified rheumatologist and internist, Dr. Kotzin is currently senior vice president and head of immunology at Nektar Therapeutics. ... The Board concluded that Dr. Kotzin should continue to serve as a member of the Board in part due to his extensive experience with developing therapeutics, particularly in the area of immunology, which is the core of our treatment focus for fostamatinib and our pipeline. |
| 2023-04-14 | Brian L. Kotzin, M.D., age 73, joined us as a director in August 2017. ... The Board concluded that Dr. Kotzin should continue to serve as a member of the Board in part due to his extensive experience with developing therapeutics, particularly in the area of immunology, which is the core of our treatment focus for fostamatinib and our pipeline. ... The following directors are currently members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Dr. Kotzin ... The following directors are currently members of the Scientific and Clinical Trial Advisory Committee: Dr. Kotzin ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2022: Brian L. Kotzin, M.D. Fees Earned or Paid in Cash ($) 75,000 Stock Awards ($) 50,250 Option Awards ($) 40,926 Total ($) 166,176. |
Data sourced from SEC filings. Last updated: 2026-03-05